Trial · NCT02930122
IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions
NCT02930122, Phase 2, Terminated, Cale Jacobs, PhD; results first posted 2021-10-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions. Trials, record NCT02930122. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02930122
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions
- NCT number
- NCT02930122
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Cale Jacobs, PhD
- Conditions
- Anterior Cruciate Ligament Tear
- Interventions
- anakinra (150mg), Saline intraarticularly
- First posted
- 2016-10-12
- Last updated
- 2021-11-24
- Results first posted
- 2021-10-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of Knee Injury and Osteoarthritis Outcome Score (KOOS) Symptom Score Between Groups | 1 year | KOOS symptoms scores range from 0 to 100, with higher scores indicating less severe symptoms. |
| Secondary | Change in CTX-II Levels From Injury to Time of Surgery | time of surgery | CTX-II levels measured by ELISA |
| Other | MRI T1rho Changes | 1 year | MRI: T1rho values in Medial and lateral femoral condyle as well as medial and lateral tibial plateau |
| Other | Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Score Between Groups | 1 year | KOOS QOL |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change of Knee Injury and Osteoarthritis Outcome Score (KOOS) Symptom Score Between Groups | 1 year | The trial was terminated due to lack of funding so an insufficient number of participants were consented to generate meaningful data. | ||
| SECONDARY | Change in CTX-II Levels From Injury to Time of Surgery | time of surgery | The trial was terminated due to lack of funding so an insufficient number of participants were consented to generate meaningful data. | ||
| OTHER_PRE_SPECIFIED | MRI T1rho Changes | 1 year | The trial was terminated due to lack of funding so an insufficient number of participants were consented to generate meaningful data. | ||
| OTHER_PRE_SPECIFIED | Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Score Between Groups | 1 year | The trial was terminated due to lack of funding so an insufficient number of participants were consented to generate meaningful data. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Anakinra | 3 | |
| Overall Study | STARTED | Placebo Control | 3 | |
| Overall Study | COMPLETED | Anakinra | 0 | |
| Overall Study | COMPLETED | Placebo Control | 0 | |
| Overall Study | NOT COMPLETED | Anakinra | 3 | |
| Overall Study | NOT COMPLETED | Placebo Control | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | 0 | 3 |
| Total, all-cause mortality | Placebo Control | 0 | 3 |
| Total, other adverse events | Arm 1 | 0 | 3 |
| Total, other adverse events | Placebo Control | 0 | 3 |
| Total, serious adverse events | Arm 1 | 0 | 3 |
| Total, serious adverse events | Placebo Control | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm 1 vs Placebo Control: deaths from any cause | Trial comparisons |
| Arm 1 vs Placebo Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02930122
GET https://conductscience.org/api/trials/v1/NCT02930122/registered